EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CytoDyn's enterprise value is $173.32 Mil.
CytoDyn's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 was $0.00 Mil. Therefore, CytoDyn's EV-to-Revenue for today is .
The historical rank and industry rank for CytoDyn's EV-to-Revenue or its related term are showing as below:
CYDY's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.83 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-06-06), CytoDyn's stock price is $0.1534.
CytoDyn's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 was $0.00. Therefore, CytoDyn's PS Ratio for today is .
CytoDyn EV-to-Revenue Historical Data
The historical data trend for CytoDyn's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CytoDyn's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoDyn's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoDyn's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where CytoDyn's EV-to-Revenue falls into.
CytoDyn's current Enterprise Value is $173.32 Mil.
CytoDyn's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoDyn's share price for today is $0.1534.
CytoDyn's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoDyn EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of CytoDyn's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYDY has been successfully added to your 